Immunology Research Center, Tabriz University of Medical Science, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Immunology Research Center, Tabriz University of Medical Science, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Biomed Pharmacother. 2016 Jul;81:305-317. doi: 10.1016/j.biopha.2016.04.011. Epub 2016 Apr 23.
Breast cancer is the most common type of cancer in women whose prevalence is increasing every year. Common strategies for diagnosis, prognosis and specific treatment of breast cancer need improvements to increase patients' survival. For this reason, there is growing number of efforts world-wide with molecular approaches. With the advent of microRNAs (miRNAs), they have been interested for almost all aspects of tumorgenesis and correlation of breast cancer and microRNAs was discovered for the first time in 2005. MiRNAs form a group of small noncoding RNAs which participate in regulation of gene expression and subsequently several biological processes and pathogenesis of various diseases. As other cancers, miRNAs involved in breast cancer are classified in two groups: the first group is tumor inducing miRNAs (also called oncomirs) that can induce tumor initiation and progression, and their expression is increased in cancerous cells. The second group is tumor suppressor miRNAs. In normal situation, tumor suppressor miRNAs prevent beginning and progression of breast cancer through suppressing the expression of various oncogenes. In this review we will give a general overview about miRNAs and breast cancer, and in the following, more discussion about tumor suppressor miRNAs, with focus on the best known of them and their targeted oncogenes and signaling pathways. Finally, we will point to application of this group of miRNAs in diagnosis, prognosis and treatment of patients.
乳腺癌是女性最常见的癌症类型,其患病率每年都在增加。诊断、预后和特定治疗乳腺癌的常见策略需要改进,以提高患者的生存率。因此,全世界都在努力采用分子方法。随着 microRNAs(miRNAs)的出现,它们几乎涉及肿瘤发生的所有方面,并且乳腺癌与 microRNAs 的相关性在 2005 年首次被发现。miRNAs 是一组小型非编码 RNA,参与基因表达的调控,随后参与多种生物过程和各种疾病的发病机制。与其他癌症一样,参与乳腺癌的 miRNAs 分为两类:第一类是诱导肿瘤的 miRNAs(也称为 oncomirs),可诱导肿瘤的起始和进展,其在癌细胞中的表达增加。第二类是肿瘤抑制 miRNAs。在正常情况下,肿瘤抑制 miRNAs 通过抑制各种癌基因的表达来预防乳腺癌的起始和进展。在这篇综述中,我们将对 miRNAs 和乳腺癌进行概述,接下来将更详细地讨论肿瘤抑制 miRNAs,重点介绍其中最著名的 miRNA 及其靶向癌基因和信号通路。最后,我们将指出这组 miRNAs 在患者诊断、预后和治疗中的应用。